I am a physical chemist with expertise in the field of colloidal science, skilled in experiments, theory and simulations to solve pharmaceutical problems – from small molecules to macromolecules like mRNA.

I have been working at AstraZeneca for over 25 years on gastrointestinal absorption, oral vaccines, molecular simulations, nanoparticle systems of poorly soluble drugs and more recently, on lipid nanoparticles and exosomes incorporating nucleic acids.

I received my PhD at Chalmers University of Technology in 1993. In 2007, I became an adjunct Professor at the Department of Chemistry and Molecular Biology, University of Gothenburg, which enhances my interaction with the academic community.


Adjunct Professor and Principal Scientist, Advanced Drug Delivery, Pharmaceutical Sciences, R&D


Succeeded in incorporating exogeneous functional mRNA molecules into exosomes, our own biological delivery vehicle


Discovered the internal structure of mRNA-containing lipid nanoparticles and how their surface could be tailored to optimize their biological function


Invented a principle to minimize unwanted side effects for mRNA-containing lipid nanoparticles

  Featured publications

Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation.

Cao E,  Lindgren A, Martinsson S,  Hu LJ, Lindfors L, Sigfridsson K, Skantze U, Michaelsson E, Trevaskis NL, Porter CJH. Journal of Controlled Release, (2019), 296: 29. Publication link

Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.

Arteta MY, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvistc AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Proceedings of the National Academy of Sciences (2018), 115: E3351. Publication link.

Nanocrystal formulations of a poorly soluble drug. 1. In vitro characterization of stability, stabilizer adsorption and uptake in liver cells.

Sigfridsson K, Skantze U, Skantze P, Johansson S, Grant I,  Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. International Journal of Pharmaceutics (2017), 518: 29.  Publication link.

Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice.

Sigfridsson K, Skantze P, Skantze U, Svensson L,  Löfgren L, Nordell P, Michaelsson E, Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. International Journal of Pharmaceutics (2017), 524: 248. Publication link.

Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction.

Krishna Dasa SS, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L,  Klibanov AL, French BA, Kelly KA. Journal of Controlled Release (2015), 220: 556.  Publication link.

Secondary Crystal Nucleation: Nuclei Breeding Factory Uncovered.

Anwar J, Khan S, Lindfors L. Angewandte Chemie (2014), 127: 14894. Publication link.

Nucleation and crystal growth in supersaturated solutions of a model drug

Lindfors L, Forssén S, Westergren J, Olsson U. Journal of Colloid and Interface Science (2008), 325: 404. Publication link.

Amorphous drug nanosuspensions.1.Inhibition of Ostwald ripening

Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Langmuir (2007), 22: 906. Publication link.

Amorphous drug nanosuspensions.2. Experimental determination of bulk monomer concentrations

Lindfors L, Forssén S, Skantze P, Skantze U, Zackrisson A, Olsson U. Langmuir (2007), 22: 911. Publication link.

Amorphous drug nanosuspensions.3. Particle dissolution and crystal growth

Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. Langmuir (2007), 23: 9866.  Publication link.